Denis Barritault

Barritault Denis serves as the CEO of OTR3 and an emeritus professor at the University Paris Est Creteil, a position held since October 2003. OTR3 specializes in translating basic research into medicinal products utilizing RGTA® (ReGeneraTing Agents), a novel therapeutic class in regenerative medicine aimed at restoring the cellular microenvironment in damaged tissues. Prior to this, Barritault Denis was a professor at the University Paris 12 from 1982 to 2003, where Barritault Denis founded and directed the Laboratoire de Recherche sur la Croissance Cellulaire, la Réparation et la Régénération tissulaires (CRRET), a CNRS unit with 30 faculty members. Barritault Denis obtained a Doctorate of Science in Biochemistry and Molecular Biology from Université Paris Cité, with studies commencing in 1975 and continuing to the present.